Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of Gastrografin for malignant bowel obstruction
ACTRN12617000125325Phase 2Completed
- Sponsor
- Mater Misericordiae University Hospital
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diatrizoate meglumine + diatrizoate sodium in malignant bowel obstruction (MBO) and cancer, sponsored by Mater Misericordiae University Hospital. Primary endpoint: Feasibility composite outcome. Started May 2017; status: completed.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
malignant bowel obstruction (MBO)cancer
Beyond the preview
Go deeper on ACTRN12617000125325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000125325.